EUGENE, Ore., Jan. 30, 2015 /PRNewswire/ -- Dr. Mark Jewell announces the first publication of 1 year outcome data involving the use of Seri Surgical Scaffold in breast reconstruction in Plastic and Reconstructive Surgery journal. The Sure-001 study is a FDA-approved study involving the use of this biologic textile for soft tissue reinforcement in two-stage breast reconstruction. Dr. Jewell is one of the developers and investigators of this product that is commercially available through Allergan: http://www.seri.com/
Seri Surgical Scaffold is a unique, first of its kind product. It works with the patient's local tissues to produce strong collagen over time and is slowly resorbed over two years' time. It is completely different than plastic surgical mesh that does not resorb.
This is the first published outcome data involving the use of a bio-engineered, ultrapure silk-based textile used for soft tissue reinforcement during reconstructive breast surgery. This peer-reviewed scientific paper was just published in Plastic and Reconstructive Surgery (February 2015). A copy is available at: http://journals.lww.com/plasreconsurg/Fulltext/2015/02000/SERI_Surgical_Scaffold,_Prospective_Clinical_Trial.4.aspx
The outcome from this study demonstrated excellent clinical outcomes, patient satisfaction, and a low incidence of adverse events in patients undergoing 2-stage breast reconstruction with Seri Surgical Scaffold. The outcome data demonstrated that this material was better than published reports involving cadaver or pig-sourced acellular dermal matrix products.
Seri Surgical Scaffold represents a major advance in ways that surgeons can use soft tissue support products to improve clinical outcomes and break the cycle of reoperation failure seen in reconstructive surgery.
SOURCE Dr. Mark Jewell, MD